GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7  by Koehler, Jacqueline A. et al.
ArticleGLP-1R Agonists Promote Normal and Neoplastic
Intestinal Growth through Mechanisms Requiring
Fgf7Graphical AbstractHighlightsd Activation of GLP-1 receptor signaling promotes gut growth
and crypt fission
d Loss of GLP-1R signaling reduces growth in models of gut
hyperplasia and tumorigenesis
d GLP-1R agonists promote small and large bowel growth via
Fgf7Koehler et al., 2015, Cell Metabolism 21, 379–391
March 3, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cmet.2015.02.005Authors
Jacqueline A. Koehler,
Laurie L. Baggio, ...,




Analogues of glucagon-like peptide-1
(GLP-1) are used to treat diabetes for their
blood glucose lowering effects. Koehler
et al. now show that GLP-1 also promotes
gut growth through Fgf7 and that loss of
GLP-1 signaling reduces growth in
models of gut hyperplasia and
tumorigenesis.Accession NumbersGSE63841
Cell Metabolism
ArticleGLP-1R Agonists Promote Normal
and Neoplastic Intestinal Growth
through Mechanisms Requiring Fgf7
Jacqueline A. Koehler,1 Laurie L. Baggio,1 Bernardo Yusta,1 Christine Longuet,1 Katherine J. Rowland,2 Xiemin Cao,1
Dianne Holland,1 Patricia L. Brubaker,2 and Daniel J. Drucker1,*
1Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON M5G1X5, Canada
2Department of Physiology, University of Toronto, Toronto, ON M5S1A8, Canada
*Correspondence: drucker@lunenfeld.ca
http://dx.doi.org/10.1016/j.cmet.2015.02.005SUMMARY
Glucagon-like peptide-1 (GLP-1) secreted from en-
teroendocrine L cells promotes nutrient disposal
via the incretin effect. However, themajority of L cells
are localized to the distal gut, suggesting additional
biological roles for GLP-1. Here, we demonstrate
that GLP-1 receptor (GLP-1R) signaling controls
mucosal expansion of the small bowel (SB) and co-
lon. These actions did not require the epidermal
growth factor (EGF) or intestinal epithelial insulin-
like growth factor (IGF1) receptors but were absent
in Glp1r/ mice. Polyp number and size were
increased in SB of exendin-4-treated ApcMin/+ mice,
whereas polyp number was reduced in SB and colon
of Glp1r/:ApcMin/+ mice. Exendin-4 increased
fibroblast growth factor 7 (Fgf7) expression in
colonic polyps ofApcMin/+mice and failed to increase
intestinal growth in mice lacking Fgf7. Exogenous
exendin-4 and Fgf7 regulated an overlapping set of
genes important for intestinal growth. Thus, gain
and loss of GLP-1R signaling regulates gut growth
and intestinal tumorigenesis.
INTRODUCTION
Gut peptides act as circulating hormones or neurotransmitters to
control appetite, gastrointestinal motility, gall bladder emptying,
pancreatic enzyme secretion, and the absorption and disposal of
ingested nutrients. The proglucagon-derived peptides (PGDPs),
encompassing glicentin, oxyntomodulin, GLP-1, and glucagon-
like peptide-2 (GLP-2), are among the best-studied products of
the enteroendocrine L cell and regulate energy ingestion, ab-
sorption, and disposal (Campbell and Drucker, 2013; Drucker
and Yusta, 2014). Analogues of GLP-1 and GLP-2 have been
approved for the treatment of diabetes and short bowel syn-
drome, respectively, further highlighting conservation of key
metabolic pathways linking gut peptide action to the control of
energy homeostasis.
GLP-1 is classically viewedas an incretin that rapidly augments
glucose-dependent insulin secretion following meal ingestion.CeGLP-1 also inhibits glucagon secretion, gastric emptying, and
food intake, leading to reduction of glycemia and weight loss.
Despite the distal location of most GLP-1-producing L cells in
the ileum and colon, GLP-1 levels rise rapidly within minutes of
meal ingestion, findings attributed to direct secretion from a sub-
set of L cells in the jejunum and a proximal-distal neuroendocrine
axis that communicatessignalsenablingsecretionofPGDPs from
the ileum and colon.
Several alternative explanations have arisen for the role and
location of distal gut L cells. Colonic L cells may function as an
energy sensor, secreting GLP-1 to modulate gut motility in
response to fatty acids and energy availability (Wichmann
et al., 2013). Alternatively, distal L cells may liberate GLP-1 in
response to microbial byproducts (Molina et al., 2014), or other
metabolites from digested nutrients (Reimann et al., 2012). A
third role for GLP-1 in the distal gut includes stimulation of
SB growth (Kissow et al., 2012; Simonsen et al., 2007); how-
ever, mechanisms linking GLP-1R signaling to augmentation of
mucosal growth remain obscure.
Here, we demonstrate that gain and loss of GLP-1R signaling
modulates intestinal growth in the SB and large bowel (LB).
Intestinal growth in Gcgr/ mice was differentially reduced in
Gcgr/:Glp1r/ versus Gcgr/:Glp2r/ mice, whereas the
intestinotrophic actions of exogenous GLP-1 and GLP-2 in
wild-type (WT) mice were mediated by distinct mechanisms.
The intestinotrophic actions of GLP-1R agonists did not require
the EGF receptor or the intestinal epithelial IGF-1 receptor,
but were mediated by GLP-1R-dependent stimulation of crypt
fission through Fgf7-dependent mechanisms. Exendin-4 in-
creased polyp size and number in ApcMin/+ mice, a model of in-
testinal tumorigenesis, whereas polyp number was significantly
reduced in Glp1r/:ApcMin/+ mice. These findings extend cur-
rent concepts of GLP-1 action in the distal gut to encompass
control of intestinal growth.
RESULTS
Endogenous GLP-1 and GLP-2 Independently Mediate
Intestinal Growth
We first assessed whether endogenous native GLP-1, acting
through the canonical GLP-1R, is capable of promoting bowel
growth in Gcgr/ mice that exhibit increased circulating levels
of GLP-1 and GLP-2 (Ali et al., 2011; Gelling et al., 2003; Gri-
goryan et al., 2012). SB and LB mass and length were increasedll Metabolism 21, 379–391, March 3, 2015 ª2015 Elsevier Inc. 379
Figure 1. GLP-1R Activation Promotes Intestinal Growth by Increasing Crypt Number Rather than Augmenting Villus Length
(A) Small bowel (SB) and large bowel (LB) weight (as a percentage of bodyweight), length, andweight/unit length in C57BL/6malemice following administration of
Ex-4 or vehicle (PBS) for 7 days. n = 5 in each group.
(B) SB and LB weight (as a percentage of body weight) and length, and SB weight/unit length of femaleGlp1r–/– andGlp1r+/+ littermate control mice administered
Ex-4 or PBS for 10 days. n = 4–6 mice per group.
(C) BrdU labeling in the jejunal crypt compartment of WTmice treated with Ex-4, EGF, or PBS followed by a 1 hr pulse with BrdU. Schematic representation of the
experimental design is shown (far right panel). Incidence of staining (BrdU labeling index) at each cell position within the crypt is shown (far left panel). Position 1
corresponds to the base of the crypt. Tissue sections were scored for total number of BrdU+ cells, BrdU+ cells in the intestinal stem cell (ISC) region (crypt base
(legend continued on next page)
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in Gcgr/ mice (Figures S1A and S1B), consistent with eleva-
tions in GLP-2, a peptide with known intestinotrophic activity
(Drucker and Yusta, 2014; Gelling et al., 2003). Nevertheless,
SB weight and length were reduced, but not normalized, while
LB mass and length remained elevated in Gcgr/:Glp2r/
mice (Figure S1B). Elimination of the GLP-1R failed to normalize
SB weight. However, SB length and LB weight and length
were normalized in Gcgr/:Glp1r/ mice (Figure S1A). Hence,
GLP-1R signaling independent of the GLP-2R mediates trophic
effects predominantly in the distal gastrointestinal tract of
Gcgr/ mice.
GLP-1R Activation Promotes Intestinal Growth by
Increasing Crypt Number
To identify mechanisms through which GLP-1R signaling pro-
motes gut growth independent of confounding metabolic pertur-
bations arising in Gcgr/ mice (Gelling et al., 2003), we treated
C57BL/6 WT mice with the clinically approved GLP-1R agonist
exenatide (Ex-4: exendin-4) for 1 week. Ex-4markedly increased
the weight, length, and weight per unit length of the SB and
significantly augmented LB weight (Figures 1A and S1C).
Furthermore, the intestinotrophic effects of Ex-4 and a long-
acting human GLP-1R agonist, liraglutide, were mediated
through the GLP-1R, as they had no effect on bowel growth in
Glp1r/ mice (Figures 1B, S1D, and S1E). Although GLP-2 in-
duces intestinal growth by increasing crypt cell proliferation
(Drucker et al., 1996), Ex-4 did not enhance cell proliferation in
the crypt compartment of the jejunum (Figure 1C) or colon (Fig-
ure S1F). In contrast, EGF increased the number of BrdU+ cells
in the intestinal stem (ISC) region and in the transit amplifying
(TA) region (Figure 1C), suggesting that GLP-1R signaling in-
duces intestinotrophic effects through mechanisms that diverge
from those activated by GLP-2 or EGF.
To determine whether the intestinotrophic actions of GLP-1R
agonists are sustained with chronic administration, we treated
micewith Ex-4 twice daily for 1month. Ex-4 increased SBweight
and length (Figures 1D and S1G) and increased the circumfer-
ence and crypt number in the proximal (Figure 1E, duodenum
and jejunum), but not the most distal region of the SB (Figure 1E,
distal ileum). Similarly, Ex-4 significantly increased the number of
crypts/cross-section in the colon (Figure 1E). In contrast, chronic
Ex-4 treatment did not increase colon crypt depth or SB crypt +
villus height (Figure 1E). These results suggest that sustained
GLP-1R activation increases crypt number, but not crypt
cell proliferation, to promote intestinal growth. Consistent with
independent contributions of endogenous GLP-1 and GLP-2columnar cells [CBCs] + ‘4+’ ISCs cells), and BrdU+ cells in the transit amplifying
from two experiments.
(D and E) WT male mice were administered exogenous Ex-4 or PBS for 4 weeks.
treated with PBS or Ex-4 for 4 weeks (left panels, magnification 340), and SB w
panels). n = 10 in each group from three experiments. (E) Circumference surroun
SB), or crypt depth (for colon) are shown for each section of intestine as indicated.
is depicted above the data. n = 6–7 mice in each group.
(F) SB weight (as a percentage of body weight), length, and weight/unit length in C
or both Ex-4 and Gly2-GLP-2 (Ex-4/GLP-2) for 10 days. n = 5 in each group.
(G) Representative histological sections of jejunum stained with H&E from mice tr
group. Magnification 340.
For (A)–(F), data are means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 versus PBS. #
GLP-2; +++p < 0.001 h[Gly2]GLP-2 versus Ex-4+ h[Gly2]GLP-2. See also Figure
Ceon bowel growth in Gcgr/ mice (Figures S1A and S1B), co-
administration of the GLP-2R agonist h[Gly2]GLP-2 (Drucker
et al., 1997) and Ex-4 significantly increased SB weight and
length to a greater extent than either peptide alone (Figures 1F
and S1H). Furthermore, histological examination revealed that
whereas jejunal circumference was increased by Ex-4, GLP-2
increased villus length (Figure 1G). Taken together, whereas
GLP-2 promotes intestinal growth by inducing crypt cell prolifer-
ation and villus elongation (Drucker and Yusta, 2014), GLP-1R
agonism promotes crypt fission and augments crypt number, re-
sulting in an increase in the width and length of the intestine.
GLP-1R Signaling Controls Polyp Burden in ApcMin/+
Mice
Subjects with obesity or type 2 diabetes exhibit increased rates
of colon cancer (Calle and Thun, 2004; Lai et al., 2013; Li et al.,
2011). Hence, we examined GLP1R expression in human colon
tumors. The GLP1R (Figure 2A) and both the GLP2R and
glucose-dependent insulinotropic polypeptide receptor (GIPR)
mRNA transcripts (Figures S2A and S2B) were expressed in hu-
man colorectal tumors, but at lower levels relative to those in
adjacent non-neoplastic colon samples from the same patients.
Glp1r transcripts were also detected in colon polyps from
ApcMin/+ mice, a murine model of intestinal tumorigenesis (Fig-
ures 2B and S3E), at lower levels relative to normal adjacent
colon or duodenum tissue (Figure 2B). Hence, the GLP-1R is
not upregulated in benign or malignant intestinal lesions of
epithelial origin. Nevertheless, Ex-4 significantly increased the
number (Figures 2C and S3A) and size (Figures 2D and S3B) of
polyps primarily in the distal SB of female (Figure 2) and male
(Figure S3) ApcMin/+ mice. In contrast, Ex-4 had no effect on
polyp burden in more proximal regions of the SB or on the num-
ber or size of polyps or aberrant crypt foci (ACF) in the colon (Fig-
ures 2E, 2F, S3C, and S3D).
To examine the physiological importance of the endogenous
GLP-1/GLP-1R system for polyp growth, we generated
ApcMin/+:Glp1r–/– mice. Strikingly, polyp burden was dramati-
cally reduced in both female and male ApcMin/+:Glp1r–/– mice.
Loss of the Glp1r resulted in one-third fewer polyps throughout
the entire SB (Figures 2G and S4A) without reducing polyp size
(Figures 2H and S4B). Furthermore, significantly fewer polyps,
but no differences in colonic ACFs or polyp diameter, were de-
tected in the colons of ApcMin/+:Glp1r–/– mice compared with
ApcMin/+:Glp1r+/+ littermates (Figures 2I, 2J, S4C, and S4D). In
addition, fewer ApcMin/+:Glp1r–/– mice developed colon polyps
(5 of 9 females and 9 of 11 males), whereas all ApcMin/+:Glp1r+/+(TA) region (positions 6–11) per hemicrypt, as indicated. n = 6 mice per group
(D) Representative histological sections of jejunum stained with H&E from mice
eight (as a percentage of body weight), length, and weight/unit length (right
ding the mucosa, number of crypts/cross section, and crypt + villus height (for
Schematic representation of the locations of the sections used for histology (H)
57BL/6 male mice following administration of PBS, Ex-4, Gly2-GLP-2 (GLP-2),
eated with PBS, Ex-4, Gly2-GLP-2 (GLP2), or both, as indicated. n = 5 in each
p < 0.05, ##p < 0.01, ###p < 0.001 Ex-4 versus h[Gly2]GLP-2, or Ex-4+h[Gly2]
S1.
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Figure 2. GLP-1R Signaling Modulates Polyp Burden in ApcMin/+ Mice
(A)GLP1R expression by qPCR analysis of RNA samples from paired normal human colon or colonic adenocarcinoma. Left panel: relativeGLP1RmRNA levels of
all 50 normal human and tumor samples. Right panel: relative mRNA levels of normal colon (N) and tumor (T) samples designated and graphed according to tumor
location. Colce (colon/cecum-proximal colon), SGM (sigmoid colon-distal region before rectum), Colon, RSGM (rectosigmoid), COLR (colorectal), Rectum,
ENBPE (en-bloc peritoneum), ABPER (abdominal peritoneal).
(B)Glp1r expression by qPCR analysis of normal (i.e., without polyps) duodenum (Duo), colon, or colon polyps of ApcMin/+mice. Data aremeans ± SE, n = 10mice
per group.
(C–F) ApcMin/+mice were administered Ex-4 or PBS for 4 weeks. Number (C) and size (D) of polyps in regions of the small bowel of female ApcMin/+mice. Number
of polyps and aberrant crypt foci (ACF) (E) and size of polyps (F) in colons of female ApcMin/+ mice. n = 9 per group. Data are means ± SE. *p < 0.05 versus PBS.
(G–J) Number (G) and size (H) of polyps in regions of the SB of female ApcMin/+:Glp1r+/+ and littermate ApcMin/+:Glp1r –/– mice. The number of polyps and ACFs (I)
and size of polyps (J) in the colons of femaleApcMin/+:Glp1r+/+ and littermate ApcMin/+:Glp1r –/– mice. n = 9 for all genotypes. Data aremeans ± SE. *p < 0.05, ***p <
0.001 ApcMin/+:Glp1r+/+ versus ApcMin/+:Glp1r –/– mice.
(legend continued on next page)
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mice (9 females and 11 males) developed at least one colon
polyp. Taken together, these results demonstrate that gain or
loss of GLP-1R signaling modifies the number of intestinal
polyps in ApcMin/+ mice.
Although GLP-2 stimulates cell proliferation (Drucker et al.,
1996), acute Ex-4 administration reduced cell proliferation in
SB polyps and decreased basal crypt cell proliferation in the
jejunum, but not the colon, of ApcMin/+ mice (Figure 2K). In
contrast, chronic Ex-4 treatment reduced the number of
apoptotic cells but had no effect on neutrophil infiltration in SB
polyps (Figures S3F and S3G). Acute Ex-4 administration
increased the phosphorylation/inactivation of GSK3 in colonic
polyps (Figure S3H), whereas chronic Ex-4 treatment increased
expression of Wnt target genes (axin2, lef1, tcf7) and the ligand
Wnt5a in colon polyps of ApcMin/+ mice (Figure 2L). Moreover,
levels of mRNA transcripts encoding the ISC markers musashi-
1 (msi-1) and achaete-scute complex-like-2 (ascl2) were upregu-
lated in colon polyps of chronically Ex-4-treated ApcMin/+ mice
(Figure 2L) as well as in the jejunum of C57BL/6 mice upon
chronic Ex-4 exposure (Figure S5A). Examination of growth fac-
tor receptor and ligand expression (Figures 2L and S3I) revealed
upregulation of Igf1mRNA transcripts in colonic polyps of chron-
ically Ex-4-treated ApcMin/+ mice. In contrast, loss of GLP-1R
signaling did not reveal significant changes in expression of
candidate growth-regulating genes (Figure S4E) or signaling
pathways (Figure S4F) in colonic polyps of ApcMin/+:Glp1r–/–
mice.
Epithelial IGF1 or EGF Receptor Signaling Pathways Are
Not Essential for GLP-1R-Mediated Intestinal Growth
A summary of selected gene expression profiles in the intestine
of Ex-4-treated mice is shown in Table S1. Ex-4 upregulated Igf1
transcripts in the jejunum and colon and areg and ereg in the
jejunum of C57BL/6 mice (Figure 3A) as well as Igf1r and areg
in the duodenum of WT (Figure S5C) and ApcMin/+ mice (Table
S1). Ex-4 also acutely induced eregmRNA levels in colon polyps
of ApcMin/+mice (Figure 3B) as well as tcf7 and tcf7l2 transcripts
in the jejunum of C57BL/6mice (Figure S5B). These findings sug-
gested that GLP-1R activation may induce receptor tyrosine
kinase IGF1R/ErbB(EGFR) (igf1, areg, ereg) pathways to regulate
intestinal growth and tumorigenesis. We therefore examined
whether the intestinal growth-promoting effects of Ex-4 or lira-
glutide were preserved in (i) mice with a conditional deletion of
the IGF-1R from intestinal epithelial cells (IE-Igf1rKO) (Rowland
et al., 2011) and (ii) Egfrwa2/wa2 (waved) mice harboring a loss-
of-function point mutation in the EGFR kinase domain (Luetteke
et al., 1994). Liraglutide increased SB weight and length in IE-
Igf1rKO mice, and colon weight trended higher in liraglutide-
treated IE-Igf1rKO and littermate control mice (Figure 3C). Ex-4
also increased SB weight, and colon weight trended higher after
Ex-4 in Egfrwa2/wa2 and heterozygote littermate controls (Fig-
ure 3D). Hence, GLP-1R agonists induce components of IGF-1(K) BrdU incorporation in SB polyps and in jejunal and colon crypt compartment
experimental design is shown (right panel). For SB polyps, BrdU+ area is shown a
from 6mice. For the jejunum and colon, tissue sections were scored for total numb
0.05, ***p < 0.001 versus PBS.
(L) qPCR analysis of colon polyps of ApcMin/+ mice treated with PBS or Ex-4 for 4
*p < 0.05, **p < 0.01, ***p < 0.001 versus PBS. See also Figures S2–S4 and Tabl
Ceand ErbB signaling pathways. However, intestinal epithelial
IGF1 or EGF receptor signaling is not essential for GLP-1R-medi-
ated induction of intestinal growth.
Fgf7 Is Required for GLP-1R-Mediated Intestinal Growth
As the intestinotrophic actions of GLP-2 in the mouse colon, but
not the small bowel, are attenuated by immunoneutralization of
keratinocyte growth factor (KGF) (Ørskov et al., 2005), we exam-
ined whether KGF, encoded by the Fgf7 gene, plays a role in the
intestinotrophic effects of GLP-1R agonists. Although Ex-4
administration did not induce Fgf7 expression in the colon of
C57BL/6mice (Figure S5E) or in the jejunum after chronic admin-
istration (Figure S5D), Ex-4 acutely increased Fgf7 mRNA levels
in the small bowel of WT mice (Figure 4A) and in colon polyps of
ApcMin/+ mice (Figure 4B). Strikingly, the intestinotrophic effects
of Ex-4 were abolished in Fgf7/ mice (Figures 4C, S6A, and
S6B). The inability of Ex-4 to increase bowel growth in Fgf7/
mice was not due to defective Glp1r expression, as levels of in-
testinal Glp1r mRNA transcripts were similar in Fgf7/ versus
littermate control mice (Figure 4G). Furthermore, the intestinal
growth factors GLP-2 (Figures 4D and S6C) and EGF (Figures
4E and S6D) robustly increased SB and LB weight in both
Fgf7/ and littermate control mice. Moreover, classical meta-
bolic and motility actions of GLP-1R agonists were preserved
in Fgf7/ mice (Figures 4F and S6E). Hence, Fgf7/ mice do
not exhibit a generalized resistance to intestinal growth factors
or GLP-1R agonists; however, the intestinal growth-promoting
actions of GLP-1R agonists are selectively mediated through
mechanisms requiring Fgf7.
Fgf7 was expressed in colon and upregulated in colonic
polyps of ApcMin/+ mice; expression of the receptor for Fgf7,
Fgfr2IIIb, was also detected in RNA from colon and colonic
polyps, and both FGF7 and FGFR2 mRNA transcripts were de-
tected in RNA from normal colon and human colonic adenocar-
cinoma (Figures 4H and 4I), in agreement with previous analyses
(Otte et al., 2000). These experiments suggest that enhanced or
disrupted GLP-1R signaling modifies normal and neoplastic in-
testinal growth via a GLP-1R-Fgf7 axis.
Overlapping Intestinal Gene Expression Profiles
Regulated by Ex-4 and Fgf7/Kgf
To identify growth-related signaling pathways activated by GLP-
1R agonists and/or Fgf7 in the gut, we carried out microarray (Il-
lumina WG-6) analysis on jejunal RNA prepared from mice 1 hr,
5 hr, and 20 hr following a single dose of Ex-4 or Fgf7. The num-
ber of genes significantly upregulated or downregulated at least
1.2-fold by Ex-4 or Fgf7 is shown in Figure 5A. Real-time PCR
independently verified that several genes were regulated by
both Ex-4 and Fgf7, including phlda1 (pleckstrin homology-like
domain, family A, member 1), asns (asparagine synthetase),
pcsk9 (proprotein convertase subtilisin/kexin type 9), mthfd2
(methylenetetrahydrofolate dehydrogenase [NAD+ dependent]),s of ApcMin/+ mice treated with Ex-4 or PBS. Schematic representation of the
s the percentage of the total area of the polyp. n = number of polyps quantified
er of BrdU+ cells per crypt. n = 6mice in each group. Data aremeans ± SE. *p <
weeks. n = 5 or 8 in each group. Data are means ± SE from three experiments.
e S1.
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Figure 3. IGF1R/EGFR Signaling Is Not Essential for the Intestinal Trophic Effects of GLP-1R Agonists
(A and B) qPCR analysis of RNA from jejunum and colon of C57BL/6 mice 4 hr after a single injection with Ex-4 or PBS (n = 5 per group) (A) or normal (polyp-free)
duodenum and colon, or colon polyps of ApcMin/+ mice 30 min after injection of Ex-4 or PBS (n = 4–5 mice per group) (B). Data are means ± SE. *p < 0.05, **p <
0.01, ***p < 0.001 versus PBS.
(C) Small bowel (SB) and large bowel (LB) weight (as a percentage of body weight and relative to PBS-treated controls), length (relative to PBS-treated controls),
and SB weight/unit length of Igf1rflox/flox, IE-Igf1r KO, and villin-Cre-ERT2+/0 mice treated with PBS or liraglutide for 8 days. n = 4–6 mice per group. Data are
expressed relative to the respective PBS-treated controls of males and females combined and are expressed as means ± SE. *p < 0.05 versus PBS.
(D) SBand LBweight (as a percentage of bodyweight), length, andSBweight/unit lengthof femaleEgfr+/wa2 andEgfrwa2/wa2mice treatedwith Ex-4 orPBS for 7 days.
n = 5 (PBS) or n = 6 (Ex-4) mice for each genotype. Data are means ± SE from two experiments. *p < 0.05, **p < 0.01 versus PBS. See also Figure S5 and Table S1.fkbp11 (FK506 binding protein 11), gar1 (GAR1 ribonucleopro-
tein homolog), and adck5 (aarF domain containing kinase 5) (Fig-
ure 5B). In contrast, Fgf7, but not Ex-4, induced the expression
of egr-1 (early growth response 1) and tff2 (trefoil factor 2),
whereas Ex-4, but not Fgf7, upregulated levels ofmmp13 (matrix
metallopeptidase 13) and Reg3b (regenerating islet-derived pro-
tein III beta) RNA transcripts (Figure 5B). Notably, several genes
induced by both Ex-4 and Fgf7, including phlda1 (Sakthianan-
deswaren et al., 2011), asns (Zhang et al., 2014), and mthfd2
(Nilsson et al., 2014), encode proteins important for regulation
of cell proliferation, migration, or survival.
Ex-4 Does Not Increase Intestinal Weight in Glp1r–/–
Mice Reconstituted with Glp1r+/+ Intestinal
Intraepithelial Lymphocytes
The Glp1r is expressed in murine intestinal intraepithelial lym-
phocytes (IELs) (http://www.immgen.org; B.Y. and D.J.D., un-
published data), and Tgd IELs have been implicated in repair of
the intestinal mucosa through Fgf7/KGF (Boismenu and Havran,
1994; Chen et al., 2002). To address whether IELs link GLP-1R
signaling to Fgf7 expression and gut growth, we generated
bone marrow chimeras by reconstituting lethally irradiated
Glp1r+/+ and Glp1r/ mice with congenic bone marrow from384 Cell Metabolism 21, 379–391, March 3, 2015 ª2015 Elsevier Inc.Glp1r+/+ donor mice. Donor chimerism, determined by flow cy-
tometry 14–16 weeks after transplant, was 95.9% ± 0.8% and
80.8% ± 4.6% in spleen and purified small intestinal IELs from
recipient mice, respectively (Figure 6A). Analysis of Glp1r
expression independently confirmed that IELs derived from
transplanted marrow repopulated the intestinal compartment
(Figure 6B). The reconstitution efficiency of Glp1r expression in
the jejunum and purified IELs of Glp1r/ recipients was
75% ± 21.4% and 90.7% ± 22.9%, respectively (Figure 6B).
Nevertheless, Ex-4 did not induce intestinal growth in Glp1r/
recipient mice, despite efficient reconstitution of Glp1r+/+ IELs
into Glp1r/ recipient mice (Figure 6C). Furthermore, levels of
Fgf7 mRNA transcripts were extremely low (1,000-fold lower
than Glp1r) in sorted small intestinal IELs (>98% purity), even
following in vitro activation (data not shown). In contrast, Fgf7
mRNA transcripts were enriched in RNA from primary SB myofi-
broblast cultures, compared with RNA isolated from jejunum
(Figure 6D). Although we detected a gene expression profile
consistent with that previously reported for myofibroblasts in
RNA from these cultures (Figure 6D), Glp1r mRNA transcripts
were not expressed at significant levels. Hence, although
Fgf7+ myofibroblasts remain a potential downstream target for
GLP-1R-dependent control of gut growth, it seems likely that
one or more additional GLP-1R+ cell types, perhaps enteric neu-
rons, are important for conveying GLP-1R-activated signals to
Fgf7-dependent stimulation of intestinal growth.
DISCUSSION
Although pharmacological administration of GLP-1R agonists
increased the mass of the rodent SB epithelium, mechanisms
connecting GLP-1R activation to intestinal growth were not
identified (Kissow et al., 2012; Simonsen et al., 2007). We
demonstrate that enhanced GLP-1R signaling in Gcgr/ mice
also mediates intestinotrophic activity not only in the SB, but
also in the colon. Importantly, increased colonic growth and
SB length evident in Gcgr/ mice were completely normalized
inGcgr/:Glp1r/mice. The complementary effects of endog-
enous native GLP-1 and GLP-2 on gut growth in Gcgr/ mice
are supported by our demonstration that exogenous Ex-4 and
h[Gly2]GLP-2 produce additive effects on SB weight and length
in WT mice. Hence, evidence from pharmacological peptide
administration and genetic disruption of PGDP receptors is
consistent with independent intestinotrophic actions of GLP-1
and GLP-2 through distinct mechanisms.
Our studies using gain and loss of GLP-1R signaling in
ApcMin/+mice reveal the importance of the GLP-1R as amodifier
of polyp size and number in a genetic model of intestinal tumor
growth. Surprisingly, GLP-1R agonists did not increase crypt
cell proliferation; rather, they expanded the mass of the epithe-
lium through stimulation of crypt fission. Although mechanism(s)
regulating crypt division/fission are not well defined, intestinal
mucosal growth primarily occurs via crypt division in neonatal
humans and rodents, whereas crypt fission occurs at very low
rates in normal adult tissue. In contrast, crypt fission is induced
in the adult intestine as part of the regenerative process following
intestinal damage, including ulcerative colitis, surgical resection,
or irradiation (Plamboeck et al., 2013a). Moreover, acquisition of
a single Apc-deficient crypt is not sufficient to promote tumori-
genesis, but rather a ‘field’ of adjacent mutated crypts, arising
through crypt fission or independent neighboring events, is
necessary for tumor initiation (Ali et al., 2015; Plamboeck et al.,
2013b). Furthermore, intestinal crypts harboring oncogenic mu-
tations can further expand through enhanced crypt fission in
both the murine (Snippert et al., 2014) and human (Greaves
et al., 2006) intestine. Taken together, our findings demon-
strating that GLP-1R activation increases crypt number in WT
mice and polyp burden in ApcMin/+ mice support the concept
that GLP-1/GLP-1R signaling regulates normal and neoplastic
intestinal growth through modulation of crypt fission.
Although GLP-1R agonists induce molecular components
of the IGF1R and ErbB signaling pathways in the murine gut,
and GLP-2R signaling promotes growth via a combination of
Igf1r- and ErbB-dependent pathways (Dube´ et al., 2006; Yusta
et al., 2009), disruption of intestinal epithelial IGF1R activity did
not abrogate the GLP-1R-dependent stimulation of intestinal
growth. Similarly, GLP-1R agonists augmented gut growth in
Egfrwa2/wa2 mice. Although insulin may potentially augment in-
testinal growth, we did not detect increased intestinal mass
following administration of GLP-1R agonists to mice with
normalization of GLP-1R-dependent insulin secretion (Lamont
et al., 2012). In contrast, although GLP-1R agonists loweredCeglucose and inhibited gastric emptying in Fgf7/ mice, activa-
tion of GLP-1R signaling failed to increase SB or LB mass in
the absence of Fgf7. Furthermore, pharmacological administra-
tion of Fgf7 increases plasma levels of the PGDPs, including
GLP-1, in rats (Goodlad et al., 2000), and FGF7 has been local-
ized to the enteric nervous system in the human colon (Rodri-
guez-Diaz et al., 2011), providing further evidence for the exis-
tence of a Fgf7-L cell axis.
The essential role of Fgf7-dependent pathways in control of
intestinal growth is further emphasized by findings that chemical
inhibition of Fgfr2IIIb signaling significantly reduced intestinal
polyp growth in ApcMin/+ mice (Pathuri et al., 2014). FGF7 and
its receptor FGFR2 are also expressed in human colon cancer
(Otte et al., 2000; Watanabe et al., 2000; Yoshino et al., 2005),
and increased FGFR2 expression in human colorectal cancer
correlated with more extensive disease, poor response to treat-
ment, and reduced survival (Li et al., 2014). Conversely, reduc-
tion of FGFR2 expression attenuates growth of human colon
cancer cells in vitro (Matsuda et al., 2011).
Complementary evidence for a subset of pathways regulated
by both GLP-1R agonists and Fgf7 derives from microarray and
gene expression studies, which identified intestinal genes co-
regulated by Fgf7 and Ex-4. We pursued the possibility that
Glp1r expression in IELsmay liberate Fgf7,which in turnpromotes
gut growth. Nevertheless, we were unable to restore GLP-1R-
dependent intestinal growth following reconstitution of GLP-1R+
IELs in Glp1r/ mice. Although limitations in the sensitivity and
specificity of reagents for detection of the murine GLP-1R (Pan-
jwani et al., 2013) and Fgf7 proteins limit current efforts to more
precisely localize cell types linking GLP-1R signaling to Fgf7-
dependent stimulation of gut growth, wedid observeFgf7expres-
sion in mouse SB myofibroblasts, whereas levels of Glp1rmRNA
transcripts were barely detectable in SB myofibroblast RNA.
The GLP-1R has been localized to the enteric nervous system
(ENS) in mice (Richards et al., 2014) and primates (Pyke et al.,
2014), and FGF7 has been detected in the human ENS, raising
the possibility that the ENS communicates a GLP-1R-dependent
signal that converges on Fgf7 and ultimately promotes crypt
fission. Although acute activation of GLP-1R signaling in enteric
neurons rapidly propagates a signal to the intestinal mucosal
epithelium, the precise downstream effectors of these signals
remain unclear (Kedees et al., 2013). Similarly, the specific cell
types and molecular mediators connecting intestinal GLP-1R
signaling to Fgf7 and crypt fission require further clarification.
The demonstration that the Fgf7/Fgfr2 axis is an important
target for the intestinotrophic actions of GLP-1R agonists raises
questions with translational implications. Although human sub-
jects with type 2 diabetes and obesity exhibit increased rates
of multiple cancers, incretin-based therapies have not been re-
ported to increase cancer incidence, and GLP-1R agonists
frequently produce weight loss, which may reduce the incidence
of cancer (Ashrafian et al., 2011; Terzic et al., 2010). Whether
long-term use of GLP-1R agonists will modify cancer risk in
obese and/or diabetic subjects is unknown and will require anal-
ysis of large numbers of treated subjects, likely from registry
studies.
Following bariatric surgery or genetic reduction of Gcgr
signaling, levels of GLP-1, GLP-2, and bile acids are increased
(Madsbad et al., 2014). Combined use of GLP-1 and GLP-2Rll Metabolism 21, 379–391, March 3, 2015 ª2015 Elsevier Inc. 385
Figure 4. GLP-1R-Mediated Intestinal Growth Is Not Observed in Fgf7–/– Mice
(A) qPCR analysis of RNA isolated from jejunum of C57BL/6 mice 15–90 min after a single injection of Ex-4 or PBS (left panel). n = 4 male mice per group.
Differences in mRNA levels of Fgf7were quantified by comparing the total AUC from 15–90 min in jejunum (inset, left panel) or from duodenum (Duo) and colon of
WT littermates of ApcMin/+ mice 6 hr after injection with Ex-4 or PBS (right panel). n = 6 in each group.
(B) qPCR analysis of RNA isolated from normal (polyp-free) duodenum (Duo) or colon or colon polyps ofApcMin/+mice 30min after injectionwith Ex-4 or PBS. n = 5
(Duo and colon) or n = 4 (colon polyps) mice per group.
For (A) and (B), data are means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 versus PBS.
(C–E) Small bowel (SB) and large bowel (LB) weight (as a percentage of tibia length), length (relative to tibia length), and SBweight/unit length of Fgf7+/+ or Fgf7/
mice treated for 10 days with PBS or (C) Ex-4 (n = 6–8 females per group), (D) Gly2-GLP-2 (n = 5–6 females per group), or (E) EGF (n = 3–4 males per group). Data
are means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 versus PBS.
(F) Intraperitoneal glucose tolerance test in Fgf7+/+ and Fgf7/ mice treated with PBS or Ex-4. n = 6 Fgf7/ and n = 10 Fgf7+/+ mice in each group.
(legend continued on next page)
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Figure 5. Intestinal Gene Expression Regulated by Both Ex-4 and Fgf7
(A) Venn diagrams summarizing the number of post hoc significant false discovery rate (FDR) corrected probes from the IlluminaMouseWhole Genome (WG-6V2)
Beadchip microarray analyses that were significantly upregulated (UP) or downregulated (DOWN) by at least 1.2-fold relative to control-treated mice following
treatment with Ex-4 or Fgf7 (KGF) from all 3 time points (1, 5, and 20 hr). 1 hr, n = 3; 5 hr, n = 4; 20 hr, n = 3.
(B) qPCR analysis of RNA isolated from jejunum of C57BL/6 mice 1 hr, 5 hr, or 20 hr after a single injection of Ex-4, Fgf7, or PBS. n = 5 male mice per group, from
three independent experiments. Data are means ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 versus PBS.agonists for the treatment of short bowel syndrome has also
been examined (Madsen et al., 2013). Although weight loss
and bariatric surgery are generally associated with reduced rates
of cancer (Sjo¨stro¨m et al., 2009), increased rates of colorectal(G) qPCR analysis of Glp1r mRNA expression in the duodenum (Duo) and colon
(H) Fgf7 and Fgfr2IIIb expression by qPCR analysis from normal (i.e., without polyp
SE and are shown relative to colon. n = 5–6 mice per group.
(I) FGF7 and FGFR2 expression by qPCR analysis of RNA samples from paired no
of all 50 human tumor and normal samples analyzed in one experiment. See also
Cecell proliferation and crypt fission have been detected in rectal
mucosal biopsies from obese subjects as long as 3 years
after bariatric surgery (Kant et al., 2011). Furthermore, a large
nationwide retrospective cohort study of 15,905 obese subjectsof Fgf7+/+ and Fgf7/ mice. n = 5 mice per group.
s) duodenum (Duo), colon, or colon polyps of ApcMin/+mice. Data are means ±
rmal human colon or colonic adenocarcinoma. Shown are relative mRNA levels
Figures S5 and S6 and Table S1.
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Figure 6. Ex-4 Does Not Increase Intestinal Weight in Glp1r–/– Mice following Reconstitution with Glp1r+/+ IELs
(A) Donor chimerism in intestinal IELs and splenocytes of recipientGlp1r+/+ andGlp1r/CD45.2+male mice reconstituted with congenic bonemarrow cells from
Glp1r+/+ CD45.1+ donor mice. Flow cytometry was performed on IELs isolated from the small intestine and splenocytes following staining with fluorescently
labeled monoclonal antibodies (mAbs). Frequency is expressed relative to total CD45+ live events.
(B) Quantitative assessment of Glp1r expression in jejunum (left panel) and small intestinal IELs (right panel) of recipient Glp1r/ male mice reconstituted with
bonemarrow fromGlp1r+/+ donormice. The Taqman expression assay targeting exons 3–4 of themurineGlp1rmRNA detects both wild-type and knockoutGlp1r
transcripts, whereas the assay targeting exons 5–6 exclusively detects the wild-type Glp1r mRNA. Glp1r transcript levels are expressed relative to the Glp1r
mRNA levels in Glp1r+/+ recipient mice (gray horizontal stripe).
(C) Small bowel (SB) weight (as a percentage of tibia length), length (relative to tibia length), SB weight/unit length, and tibial length of recipient Glp1r+/+ and
Glp1r/mice 14–16 weeks after reconstitution treated with PBS or Ex-4 for 10 days. n = 8–10males per group. Shown are combined data from two independent
bone marrow transfer experiments. Data are means ± SE. *p < 0.05 versus PBS.
(D) qPCR analysis of RNA isolated from jejunum (Jej), or primary cultures of myofibroblasts (Myofib) prepared from mouse small intestine. Gene expression was
assessed on cells at passage 3. Data are means ± SD from two independent experiments, comprised of two separate cultures, each derived from a separate
mouse (n = 4 cultures).
388 Cell Metabolism 21, 379–391, March 3, 2015 ª2015 Elsevier Inc.
treated with bariatric surgery revealed a significantly increased
incidence of colorectal cancer, relative to obese control subjects
(Derogar et al., 2013). Moreover, the incidence rate for develop-
ment of colorectal cancer progressively increased with length of
time after bariatric surgery (Derogar et al., 2013). However, the
importance and mechanistic underpinning of these findings re-
mains unclear and will require additional investigation.
ApcMin/+ mice represent the most widely used genetically
defined murine model for intestinal tumorigenesis and harbor a
genetic mutation in the gene underlying the development of co-
lon cancer in human subjects with familial adenomatous polypo-
sis (Nishisho et al., 1991). Although theApcMin/+mouse exhibits a
propensity for small intestinal tumors and is an imperfect model
for human colon cancer studies, loss of the APC tumor suppres-
sor gene and activation of the Wnt/beta-catenin pathway are
common genetic features of human colon cancer. Our data link-
ing GLP-1R signaling to the control of murine gut growth may
have translational implications for settings characterized by sus-
tained elevations of levels of one ormore intestinotrophic PGDPs
in the treatment of metabolic disorders.EXPERIMENTAL PROCEDURES
Reagents, Animals, and Treatments
Exendin-4 (Ex-4) was from Chi Scientific, liraglutide was from Novo Nordisk,
the DPP-4-resistant analog human h[Gly2]GLP-2 was from Pepceutical, re-
combinant mouse EGF was from Bachem, SAFE human recombinant KGF
was from eBioscience, and tamoxifen was from MP Biomedicals. Peptides
were dissolved in PBS (vehicle) and administered to mice by either intraperito-
neal (i.p.) or subcutaneous (s.c.) injection at doses of Ex-4 (10 nmol/kg, BID),
liraglutide (50 or 75 mg/kg, BID), h[Gly2]GLP-2 (2.5 mg/mouse BID), or EGF
(0.25 mg/kg, BID) unless otherwise specified. The doses of GLP-1R agonists
employed were biologically active in the gut without producing significant
weight loss. All animal experiments were approved by the Animal Care Com-
mittee of the Mount Sinai Hospital. Mice were bred at the Toronto Centre for
Phenogenomics animal facility and were maintained on a standard diet and
a 12 hr light/12 hr dark cycle.
C57BL/6J-ApcMin/+, Fgf7–/– (B6.129-Fgf7tm1Efu), Egfrwa2/wa2 (a/a Egfrwa2/J),
and C57BL/6J mice were from The Jackson Laboratory. Gcgr/ mice in the
C57BL/6 background (Gelling et al., 2003) were crossed withGlp1r/ (Scroc-
chi et al., 1996) or Glp2r/ (Lee et al., 2012) mice in the same genetic back-
ground to generate Gcgr+/:Glp1r+/ or Gcgr+/:Glp2r+/ mice, which were
bred to generate Gcgr/:Glp1r/ or Gcgr/:Glp2r/ and littermate con-
trols. Male Gcgr/:Glp2r/ mice and age- and sex-matched littermate con-
trols (n = 10–20) were approximately 36–38 weeks old at the time of sacrifice.
Male Gcgr/:Glp1r/ and age- and sex-matched littermate controls (n = 9–
13) were 20–22 weeks old at sacrifice. ApcMin/+ mice were crossed with female
Glp1r/ mice to generate ApcMin/+:Glp1r+/ and Apc+/+:Glp1r+/ mice. Male
ApcMin/+:Glp1r+/ were bred with female Apc+/+:Glp1r+/ to generate
ApcMin/+:Glp1r+/+ and ApcMin/+:Glp1r/ mice. Investigators were blinded to
genotype and treatment at the time of assessment.
Intestinal Growth
Unless otherwise indicated, non-fasted mice were euthanized by CO2 inhala-
tion the morning following the last injection (12 hr after the last injection). Fe-
male Glp1r–/– and WT (Glp1r+/+) littermate control mice (11 weeks old) were
administered Ex-4 (s.c.) or PBS for 10 days, whereas male Glp1r–/– and WT
(Glp1r+/+) littermate control mice (11 weeks old) were administered liraglutide
(75 mg/kg, i.p., BID) or PBS for 10 days. C57BL/6 male mice (11 weeks old)
were administered exogenous Ex-4 (s.c.), h[Gly2]GLP-2 (s.c.), both Ex-4 and
h[Gly2]GLP-2 (s.c.), or PBS for 10 days. Female Egfr+/wa2 and Egfrwa2/wa2
mice (8–12 weeks old) were treated with Ex-4 (i.p.) or PBS for 7 days.
Fgf7+/+ (WT) or Fgf7/ mice (8–13 weeks old) were treated with Ex-4 (s.c.),
h[Gly2]GLP-2 (s.c.), or EGF (s.c.) for 10 days. IE-Igf1rKO mice were generatedCeas described (Rowland et al., 2011). Cre recombinase was induced in mice
aged 8–11 weeks by daily injection of tamoxifen (100 ml i.p., 10 mg/ml) for
5 days. Age- and sex-matched littermate Igf1rflox/flox and villin-Cre-ERT2+/0
mice were controls and were also treated with tamoxifen. Approximately
24 hr after the final tamoxifen injection, mice were injected s.c. with PBS or lir-
aglutide (50 mg/kg, BID) for 8 days.Micewere fasted overnight before sacrifice.
See also Supplemental Experimental Procedures.
Glucose Tolerance Tests and Assessment of Gastric Emptying
Glucose tolerance (8–11 weeks old) and acetaminophen absorption (12–
15 weeks old) tests to assess gastric emptying were carried out Fgf7+/+ or
Fgf7/ mice as described (Lamont et al., 2012).
Statistical Analysis
Results are expressed as mean ± SE. Statistical significance was assessed by
one-way or two-way ANOVA using Bonferroni’s multiple comparison post test
and, where appropriate, by unpaired Student’s t test using GraphPad Prism 5
(GraphPad Software). Data were excluded from analysis if considered an
outlier by the Grubbs’ test (GraphPad Software). A p value < 0.05 was consid-
ered to be statistically significant.
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